Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis

Affiliations

• ¹ Department of Dermatology, University Hospital, Zurich, Switzerland.
• ² Gastroenterology, University Hospital, Basel, Switzerland.
• ³ Translational Immunology, Department of Biomedicine, University Hospital, Basel, Switzerland.
• ⁴ Institute of Immunity and Transplantation, University College London, Royal Free Campus, London, United Kingdom.
• ⁵ Center for Chronic Immunodeficiency, Medical Center-Faculty of Medicine, University of Freiburg, Freiburg, Germany.
• ⁶ Institute of Pathology, Cantonal Hospital Graubünden, Chur, Switzerland.
• ⁷ Department of Medicine (Solna), Karolinska Institutet, Stockholm, Sweden; Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
• ⁸ Immunobiology Lab, Department of Biomedicine, University Hospital, Basel, Switzerland.
• ⁹ Immunodeficiency Lab, Department of Biomedicine, University Hospital, Basel, Switzerland.
• ¹⁰ SIB Swiss Institute of Bioinformatics and Biozentrum, University of Basel, Basel, Switzerland.
• ¹¹ Endocrinology, University Hospital, Basel, Switzerland.
• ¹² Translational Neuroimmunology, Department of Biomedicine, University Hospital, Basel, Switzerland.
• ¹³ Molecular Immune Regulation, Department of Biomedicine, University Hospital, Basel, Switzerland.
• ¹⁴ Division of Medical Immunology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland.
• ¹⁵ Rheumatology, University Hospital, Basel, Switzerland.
• ¹⁶ Department of Internal Medicine, Kantonsspital Graubünden, Chur, Switzerland.
• ¹⁷ Immunodeficiency Lab, Department of Biomedicine, University Hospital, Basel, Switzerland. Electronic address: mike.recher@usb.ch.